Trials / Withdrawn
WithdrawnNCT04047836
Vaping High vs. Low Nicotine E-Liquid
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study will examine the effects of electronic cigarette e-liquid nicotine content in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=36). The specific aim is to determine the impact of nicotine content of e-liquid on nicotine pharmacology, systemic exposure to toxic volatile organic compounds, and short-term cardiovascular effects.
Detailed description
This is a within-subjects, crossover design of advanced electronic cigarette users in which we will examine nicotine pharmacokinetics, subjective effects, daily nicotine intake and nicotine titration, short-term cardiovascular effects, and toxicant exposure when participants are using low vs. high nicotine e-liquids. Hypothesis 1: E-cigarette users will titrate their intake of nicotine such that they will inhale fewer aerosol toxicants and suffer less harm to health when using higher vs. lower nicotine content e-liquids. Hypothesis 2: Compared to low nicotine, high nicotine e-liquid use will have similar cardiovascular effects throughout the day (due to compensatory behavioral changes), with similar effects on heart rate, blood pressure, and catecholamine release. Hypothesis 3: Exposure to volatile organic compounds (VOCs) will be lower when vaping high nicotine e-liquids compared to low nicotine e-liquids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Low Nicotine E-Liquid | Participants will vape e-liquid with nicotine concentration of 3 mg/ml. |
| OTHER | Medium or High Nicotine E-Liquid | Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid. |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2019-08-07
- Last updated
- 2023-08-22
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04047836. Inclusion in this directory is not an endorsement.